Su	bstitute for form 1449/PTO				COMPLETE IF KNOWN	•
I	NFORMATION I	DISCL	OSURE	Application Number	10/564,458	
C	TATEMENT BY	A DDI	I CO A NUTC	Filing Date	July 22, 2004	
3	IAIEWENIDI	APPL	ICANI	First Named Inventor	Anderson, Annaliesa S. et al	•
			•	Group Art Unit	1645	,
	(use as many sheets	as neces	isary)	Examiner Name	AUG 18 1000	F/CE
Sheet	1	of	3	Attorney Docket Number	21569YP	T

			T DOCUMENTS	
Examiner nitials*	Cite No.	U.S. Patent Docur	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY

		· · · · · · · · · · · · · · · · · · ·		

	FOREIGN PATENT DOCUMENTS							
Foreign Patent Document					V 65	Date of Publication of		
Examiner Initials*	Cite No.	Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY		
/S.D./		wo	2003/011899		University of Sheffield, Biosynexus Incorporated	02/13/2003		
/S.D./		wo	2002/102829		Inhibitex, Inc.; The Provost Fellows and Scholars of the College of the Holy and Undivided Trinity of Queens Elizabeth	12/27/2002		
SHORDHOUS SHORE					Near Dublin; Universita Degli Studi Di Pavia			
/S.D./		wo	02/094868		Chiron SRL.	11/28/2002		
/S.D./		wo	02/077183		Elitra Pharmaceuticals, Inc.	10/03/2002		
/S.D./		wo	02/059148 A3		Intercell AG	08/01/2002		
/S.D./		wo	02/059148 A2		Cistem Biotechnologies GMBH	08/01/2002		
/S.D./		wo	01/98499		University of Sheffield; Biosynexus Incorporated	12/27/2001		
/S.D./		EP	0 786 519		Human Genome Sciences, Inc.	07/03/1997		
/S.D./		РСТ	WO2007/089470A2		Merck & Co., Inc.	08/09/2007		

Examiner Signature	/S. Devi/	Date Considered	11/29/2008

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

, Su	Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT	COMPLETE IF KNOWN			
		DIS	CLOSURE	Application Number	10/564,458
C	TATERATERIT DV	A TO	DIICANT	Filing Date	July 22, 2004
3	IAIEMENI DI	AI	FLICANI	First Named Inventor	Anderson, Annaliesa S. et al.
			,	Group Art Unit	1645
	(use as many sheets	as n	ecessary)	Examiner Name	
Sheet	2	of	3	Attorney Docket Number	21569YP

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.					
/S.D./		Andrade, M. et al. "NEAT: a domain duplicated in genes near the components of a putative Fe3+ siderophore transporter from Gram-positive pathogenic bacteria", Genome Biology, 2002, Vol. 3, pp. 0047.1-0047.5					
/S.D./		Baba, T. et al. "Genome and virulence determinants of high virulence community-acquired MRSA", The Lancet, 2002, Vol. 359, pp. 1819-1827					
/S.D./		Buckholz, R. et al. "Yeast Systems for the Commercial Production of Heterologous Proteins", Bio/Technology, 1991, Vol. 9, pp. 1067-1072					
/S.D./		Eckart, M. et al. "Quality and authenticity of heterologous proteins synthesized in yeast", Current Opinion in Biotechnology, 1996, Vol. 7, pp. 525-530					
/S.D./		Etz, H. et al. "Identification of <i>in vivo</i> expressed vaccine candidate antigens from <i>Staphylococcus aureus</i> ", PNAS, 2002, Vol. 99, pp. 6573-6578					
/S.D./		Fattom, A. et al. "Synthesis and Immunologic Properties in Mice of Vaccines Composed of Staphylococcus aureus Type 5 and Type 8 Capsular Polysaccharides Conjugated to Pseudomonas aeruginosa Exotoxin A", Infection and Immunity, 1990, Vol. 58, pp. 2367-2374					
/S.D./		Josefsson, E. et al. "Protection against Experimental Staphylococcus aureus Arthritis by Vaccination with Clumping Factor A, a Novel Virulence Determinant", The Journal of Infectious Diseases, 2001, Vol. 184, pp. 1572-1580					
/S.D./		Kersten, G. et al. "Liposomes and ISCOMs", Vaccine, 2003, Vol. 21, pp. 915-920					
/S.D./		Klein, J. et al. "Analysis of Aluminum Hydroxyphosphate Vaccine Adjuvants by 27A1 MAS NMR", Journal of Pharmaceutical Sciences, 2000, Vol. 89, pp. 311-321					
/S.D./		Kuroda, M. et al. "Whole genome sequencing of meticillin-resistant <i>Staphylococcus aureus</i> ", The Lancet, 2001, Vol. 357, pp. 1225-1240					
/S.D./		Lathe, R. "Synthetic Olignucleotide Probes Deduced from Amino Acid Sequence Data Theoretical and Practical Considerations", J. Mol. Bio., 1985, Vol. 183, pp. 1-12					
/S.D./		Mamo, W. et al. "Vaccination with Staphylococcus aureus fibrinogen binding proteins (FgBPs) reduces colonisation of S. aureus in a mouse mastitis model", FEMS Immunology and Medical Microbiology, 1994, Vol. 10, pp. 47-54					
/S.D./		Mazmanian, S. et al. "Passage of Heme-Iron Across the Envelope of Staphylococcus aureus", Science, 2003, Vol. 299, pp. 906-909					
/S.D./		Mazmanian, S. et al. "Sortase-catalysed anchoring of surface proteins to the cell wall of Staphylococcus aureus", Molecular Microbiology, 2001, Vol. 40, pp. 1049-1057					
/S.D./		Morrissey, J. et al. "Conservation, Surface Exposure, and In Vivo Expression of the Frp Family of Iron-Regulated Cell Wall Proteins in <i>Staphylococcus aureus</i> ", Infection and Immunity, 2002, Vol. 70, pp. 2399-2407					

Examiner Signature	/S. Devi/	Date Considered	11/29/2008

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

				0. 3.	FAIGH AND TRANSPORT OF COMMISSION	
•	Substitute for form 1449/PTO			COMPLETE IF KNOWN		
	INFORMATION	DIS	CLOSURE	Application Number	10/564,458	
	STATEMENT BY	7 A TD	DIICANT	Filing Date	July 22, 2004	
	SIAIEMENI BI	Ar	PLICANI	First Named Inventor	Anderson, Annaliesa S. et al.	
			,	Group Art Unit	1645	
	(use as many sheet.	s as n	ecessary)	Examiner Name		
Sheet	3	of	3	Attorney Docket Number	21569YP	

		NON PATENT LITERATURE DOCUMENTS
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
/S.D./		Nilsson, I. et al. "Vaccination with a Recombinant Fragment of Collagen Adhesin Provides Protection against Staphylococcus Aureus-mediated Septic Death", J. Clin. Invest., 1998, Vol. 101, pp. 2640-2649
/S.D./		O'Hagan, D. "Recent Developments in Vaccine Delivery Systems", Current Drug Targets - Infectious Disorders, 2001, Vol. 1, pp. 273-286
/S.D./		Pichuantes, S. et al. "Expression of Heterologous Gene Products in Yeast", Protein Engineering: Principles and Practice, Edited by Jeffrey L. Cleland and Charles S. Craik, 1996, Chapter 5, pp. 129-161
/S.D./		Rimmelzwaan, G. et al. "A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM vaccines and conventional vaccines", Vaccine, 2001, Vol. 19, pp. 1180-1187
/S.D./		Schneewind, O. et al. "Cell wall sorting signals in surface proteins of Gram-positive bacteria", The EMBO Journal, 1993, Vol. 12, pp. 4803-4811
/S.D./		Sharp, P. et al. "Synonymous Codon Usage in Saccharomyces cerevisiae", Yeast, 1991, Vol. 7, pp. 657-678
/S.D./		Shinefield, H. et al. "Use of a Staphylococcus Aureus Conjugate Vaccine in Patients Receiving Hemodialysis", N. Engl. J. Med., 2002, Vol. 346, pp. 491-496
/S.D./		Taylor, J. et al. "Transferrin binding in <i>Staphylococcus aureus</i> : involvement of a cell wall-anchored protein", Molecular Microbiology, 2002, Vol. 43, pp. 1603-1614
/S.D./		Vogel, F. "Improving Vaccine Performance with Adjuvants", Clinical Infectious Diseases, 2000, Vol. 30, (Suppl 3), pp. S266-S270
/S.D./	X	PCT/US2008/006791 International filing date 5/29/2008; ;Merck & Co., Inc.
NO DESCRIPTION OF THE PROPERTY	00000000000	
	· · · ·	
	_	

Examiner Signature	/S. Devi/	Date Considered	11/29/2008